Two Diabetes Drugs, One Powerful Punch: Real-World Data Reveal Semaglutide Plus SGLT2 Inhibitor Benefits
A post hoc analysis of the SCHOLAR study found that over 42 percent of Chinese adults starting semaglutide also took ...
A post hoc analysis of the SCHOLAR study found that over 42 percent of Chinese adults starting semaglutide also took ...
A propensity score-matched cohort study of more than 14,000 Slovak patients with type 2 diabetes found that structured education within ...
A new commentary explains how the tightly regulated, slowly renewing beta-cell mass of the pancreas creates critical therapeutic windows for ...
A Japanese randomized trial will compare the SGLT2 inhibitor tofogliflozin with glimepiride to determine whether popular diabetes drugs erode skeletal ...
A large real-world study found that adults with type 2 diabetes and atherosclerotic cardiovascular disease who started oral semaglutide had ...
A new meta-analysis finds that combining SGLT2 inhibitors with GLP-1 receptor agonists is associated with lower risks of myocardial infarction ...
The ongoing T-BEAT observational study is evaluating real-world glycemic and weight outcomes of tirzepatide versus oral semaglutide in Japanese adults ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine